Home
/
Patient hub
/
CAR T-cell therapy treatment...

CAR T-cell therapy phases

CAR T-cell therapy consists of multiple phases, starting with an initial screening phase and ending with continued follow-ups upon going through infusion.

On this page, you can learn more about the different phases and browse through resources from various sources selected by the T2EVOLVE consortium.

Infographic from the Mayo Clinic CAR-T Cell Therapy Program.

For more from the Mayo Clinic, see here.

;

T2EVOLVE_CART Timeline_PatientsAmpHeight6

Additional resources

The CAR T-CELL THERAPY/CLINICAL TRIAL JOURNEY: A Guide for Patients and Carers

The NA-ATTC is pleased to offer The CAR T-Cell Therapy Clinical Trial Journey – A Guide for Patients and Carers in partnership with Autolus Therapeutics. This Guide is intended for people who are either considering enrolling in or are already enrolled in a CAR T-cell therapy clinical trial. It contains information for both patients and those who care for them (92 pages).

Infographic on CAR T Cell Therapy Treatment Experience

Infographic from Bristol Myers Squibb.

Cell therapy treatment experience fact sheet (1 page).

Learn more

Yourcartguide.co.uk

Information and advice on CAR T Cell Therapy by Gilead, helping patients through CAR T Cell treatment.

Visit website

Webinar | Doctor and patients' perspective on myeloma CAR-T

Recording of webinar organised by Myeloma Patients Europe (MPE) on 14 February 2023.

This webinar includes the participation of Prof. Dr. Michel Delforge, Professor of Medicine and Clinical Head of Haematology at the University Hospital Leuven, Belgium, and two myeloma patients who have received CAR-T treatment: Tamra Fine, from the Netherlands, and William Kenneth Casler, from France.

Learn more from Myeloma Patients Europe

The CAR T-Cell Therapy Clinical Journey Guide

This glossary from the Advanced Therapy Treatment Centres (ATTC) allows patients to look up terms related to CAR T.

Explore the glossary

Please note, the list of resources presented is not exhaustive and is regularly updated.

The T2EVOLVE consortium followed an internal process in order to evaluate and select the material shared under the Patient material hub. This selection is limited to material freely available. T2EVOLVE consortium makes no representation or warranty as to the completeness or accuracy of the information contained herein.